Exacerbations of chronic obstructive pulmonary disease

被引:277
作者
Celli, B. R.
Barnes, P. J.
机构
[1] Tufts Univ, Sch Med, Caritas St Elizabeth Med Ctr, Boston, MA 02111 USA
[2] Imp Coll, Natl Heart & Lung Inst, London, England
关键词
bacterial infection; exacerbation; health status; inflammation; viral infection;
D O I
10.1183/09031936.00109906
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Exacerbations of chronic obstructive pulmonary disease are of major importance in terms of their prolonged detrimental effects on patients, the acceleration in disease progression and high healthcare costs. There is still debate about how exacerbations should be defined and graded, and their mechanisms are poorly understood. The major causal agents are either bacteria or viral infections, or a combination of the two. Noninfective causes include air pollution and pulmonary embolus but, in some patients, no cause is identified. Exacerbations represent an increase in the inflammation that is present in the stable state, with increased numbers of inflammatory cells (particularly neutrophils), cytokines, chemokines and proteases in the airways, and increased concentrations of certain cytokines and C-reactive protein in the blood. There are presently no reliable biomarkers with which to predict exacerbations. Exacerbations have a long-lasting adverse influence on health status. High doses of bronchodilators are the mainstay of treatment and systemic corticosterolds have some benefit. The routine use of antibiotics remains controversial but they are of benefit with exacerbations of a bacterial origin. Noninvasive ventilation is beneficial in preventing the need for intubation and its important complications but it is not certain whether its use in stable patients prevents exacerbations. Although important advances have been made, more effective treatments are needed in the future for prevention and treatment of exacerbations.
引用
收藏
页码:1224 / 1238
页数:15
相关论文
共 161 条
  • [41] Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations
    Dentener, MA
    Creutzberg, EC
    Schols, AMWJ
    Mantovani, A
    van't Veer, C
    Buurman, WA
    Wouters, EFM
    [J]. THORAX, 2001, 56 (09) : 721 - 726
  • [42] Acute exacerbation of COPD - Factors associated with poor treatment outcome
    Dewan, NA
    Rafique, S
    Kanwar, B
    Satpathy, H
    Ryschon, K
    Tillotson, GS
    Niederman, MS
    [J]. CHEST, 2000, 117 (03) : 662 - 671
  • [43] Effects of noninvasive ventilation on pulmonary gas exchange and hemodynamics during acute hypercapnic exacerbations of chronic obstructive pulmonary disease
    Diaz, O
    Iglesia, R
    Ferrer, M
    Zavala, E
    Santos, C
    Wagner, PD
    Roca, J
    RodriguezRoisin, R
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 156 (06) : 1840 - 1845
  • [44] Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease
    Donaldson, GC
    Seemungal, TAR
    Bhowmik, A
    Wedzicha, JA
    [J]. THORAX, 2002, 57 (10) : 847 - 852
  • [45] Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease
    Donaldson, GC
    Seemungal, T
    Jeffries, DJ
    Wedzicha, JA
    [J]. EUROPEAN RESPIRATORY JOURNAL, 1999, 13 (04) : 844 - 849
  • [46] ELLIS DA, 1978, BRIT J DIS CHEST, V72, P115, DOI 10.1016/0007-0971(78)90020-7
  • [48] The impact of aging and smoking of the future burden of chronic obstructive pulmonary disease -: A model analysis in the Netherlands
    Feenstra, TL
    van Genugten, MLL
    Hoogenveen, RT
    Wouters, EF
    Rutten-van Mölken, MPMH
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (04) : 590 - 596
  • [49] Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes - The insulin resistance atherosclerosis study
    Festa, A
    D'Agostino, R
    Tracy, RP
    Haffner, SM
    [J]. DIABETES, 2002, 51 (04) : 1131 - 1137
  • [50] Chronic subclinical inflammation as part of the insulin resistance syndrome -: The Insulin Resistance Atherosclerosis Study (IRAS)
    Festa, A
    D'Agostino, R
    Howard, G
    Mykkänen, L
    Tracy, RP
    Haffner, SM
    [J]. CIRCULATION, 2000, 102 (01) : 42 - 47